← Back to Clinical Trials
Recruiting NCT07648953

NCT07648953 Microvideos for Improving HPV Vaccination Among Childhood Cancer Survivors

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07648953
Status Recruiting
Phase
Sponsor University of Utah
Condition HPV Vaccination
Study Type INTERVENTIONAL
Enrollment 55 participants
Start Date 2026-08
Primary Completion 2027-05

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 26 Years
Study Type INTERVENTIONAL
Interventions
Microvideos: HPV Vaccination Education

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 55 participants in total. It began in 2026-08 with a primary completion date of 2027-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This exploratory mixed-methods study aims to examine receipt of treatment and decision-making among rural cancer patients in Utah. Guided by Conceptual Model of Healthcare Access, the study will integrate, survey and cancer registry data with patient interviews to better understand how travel burden, socioeconomic conditions, health literacy, and other contextual factors shape treatment location and access to care . While the setting of this research is specific to Utah, a state with vast rural regions and only one National Cancer Institute (NCI)-designated cancer center, the findings may inform policy and practice improvements in other states with similar geographic and healthcare infrastructure. Thus, the study has potential relevance for advancing rural cancer equity nationwide. Understanding how rural cancer patients make treatment decisions is essential to addressing persistent disparities in cancer care access and outcomes. While geographic barriers and structural inequities are well-documented, less is known about the individual and contextual factors that shape patients' choices about where and how to receive treatment. This mixed-methods study will examine receipt of treatment, decision-making, and patient experience among rural cancer patients in Utah, with attention to travel burden, referral pathways, health literacy, and perceived barriers to care.

Eligibility Criteria

Inclusion Criteria: * Eligible participants include cancer survivors who are currently ages 18-26 years and who were diagnosed with childhood cancer (ages 0-26 at diagnosis) in the past ten years. * Currently use Facebook or willing to create a Facebook account to use for the duration of the study. * At the time of enrollment, have not completed all recommended doses of the HPV vaccine. Exclusion Criteria: * Unable to speak and understand English. * Participants who take part in the Aim 1 focus groups will be ineligible for the Aim 2 social media group. * Participants who are fully vaccinated for HPV will be ineligible as the goal of Aim 2 is to evaluate the feasibility of the social media campaign for improving vaccine intention among HPV unvaccinated individuals.

Contact & Investigator

Central Contact

Echo Warner, MPH, PhD, SB

✉ echo.warner@hci.utah.edu

📞 801-244-7040

Principal Investigator

Echo Warner, MPH, PhD, SB

PRINCIPAL INVESTIGATOR

Huntsman Cancer Institute

Frequently Asked Questions

Who can join the NCT07648953 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 26 Years, studying HPV Vaccination. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07648953 currently recruiting?

Yes, NCT07648953 is actively recruiting participants. Contact the research team at echo.warner@hci.utah.edu for enrollment information.

Where is the NCT07648953 trial being conducted?

This trial is being conducted at Salt Lake City, United States.

Who is sponsoring the NCT07648953 clinical trial?

NCT07648953 is sponsored by University of Utah. The principal investigator is Echo Warner, MPH, PhD, SB at Huntsman Cancer Institute. The trial plans to enroll 55 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology